OrSense receives EU approval for non-invasive haemoglobin and pulse
oximetry monitoring system
8 April 2009
OrSense Ltd has received a European CE Mark for its NBM-200MP, a
multi-parameter sensor for non-invasive continuous hemoglobin, low
signal oximetry and pulse rate measurements.
"We are excited about receiving the European CE approval for
NBM-200MP. This is an important milestone for OrSense in the path for
developing and marketing our unique non-invasive multi-parameter blood
monitoring device, which is expected to enhance the quality of treatment
and reduce operational costs in hospitals," said Lior Ma'ayan, CEO of
OrSense. “Upon receiving the CE mark, we will soon initiate sales in
various counties in Europe.”
The Orsense NBM-200MP blood monitor
Hemoglobin (Hb) level, a parameter which indicates haemorrhage or
anaemia, is a key measurement in hospitals and outpatient wards.
However, current hemoglobin measurements are invasive, time consuming,
labour intensive and costly.
Non-invasive pulse oximetry has become a standard of care throughout
the medical world, yet it has been known to provide erroneous oxygen
saturation readings in states of low perfusion, low cardiac output
and/or low blood flow.
The NBM-200MP system offers for the first time a non-invasive,
continuous and accurate measurement of oxygen saturation under all
physiological conditions, as well as a unique, breakthrough non-invasive
solution for accurate continuous and spot Hb measurements.
Bookmark this page